LIFE News and Press, aTyr Pharma Inc. From 03/21/23

Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bi...

SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, and the Foundation for Sarcoidosis Research (FSR), the leadi...

2023-03-10 17:12:09 ET aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Conference Call March 9, 2023 5:00 P.M. ET Company Participants Ashlee Dunston - Director, Investor Relations & Corporate Communications Sanjay Shukla - President & Chief Executive Officer J...

2023-03-09 16:02:57 ET aTyr Pharma press release ( NASDAQ: LIFE ): Q4 GAAP EPS of -$0.26 beats by $0.22 . Revenue of $10.4M beats by $10.15M . Based on the company’s current operational plans and existing cash, LIFE believes the company’s cas...

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in 2023. February 2023 follow-on common stock offering of approxim...

2023-03-08 17:35:28 ET Major earnings expected after the bell on Thursday include: Oracle corporation ( ORCL ) DocuSign ( DOCU ) Wheaton Precious Metals Corp. ( WPM ) Bionano Genomics ( BNGO ) Ulta Beauty  (ULTA0) For further details see: ...

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 20...

Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeuti...

Vancouver, Kelowna, Delta, BC - February 10, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Psychedelics, EV Metals and Mining. Today's stocks have been added to our lists of...

aTyr Pharma ( NASDAQ: LIFE ) shares fell over 7% premarket on Thursday after the biotherapeutics company priced its public offering of 22,225,000 shares at $2.25 per share. Underwriters have been granted a 30-day option to purchase up to an additional 3,333,750 shares at the p...